Insilico Medicine, Inc.
Insilico Medicine, Inc., a pioneering biotechnology firm headquartered in Hong Kong, is at the forefront of artificial intelligence-driven drug discovery and development. Founded in 2014, the company has rapidly established itself as a leader in the industry, leveraging advanced machine learning techniques to accelerate the drug development process. With a focus on areas such as ageing research and disease modelling, Insilico Medicine offers unique solutions that integrate AI with biology, enabling the identification of novel drug candidates and biomarkers. The company’s innovative platform has garnered significant attention, leading to partnerships with major pharmaceutical firms and academic institutions. Recognised for its contributions to the field, Insilico Medicine continues to push the boundaries of traditional drug discovery, positioning itself as a key player in the evolving landscape of biotechnology.
DitchCarbon Score
How does Insilico Medicine, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Insilico Medicine, Inc.'s score of 20 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Insilico Medicine, Inc.'s reported carbon emissions
Insilico Medicine, Inc., headquartered in Hong Kong, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, as a company in the biotechnology sector, Insilico Medicine may be influenced by industry standards and practices regarding carbon emissions and climate commitments. It is essential for companies in this field to adopt robust climate strategies to mitigate their environmental impact and contribute to global sustainability goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Insilico Medicine, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
